Proceedings of the National Academy of Sciences · 2010 · 266 citations · 21 references
Life SciencesBiotechnologyMolecular BiologyGene ExpressionGene RegulationSynthetic BiologyGene Expression RegulationRna EngineeringGene Expression ControlRibozyme EngineeringRna Regulatory CircuitsRna SensorsRna-based Gene RegulationRna-based Gene TherapySynthetic RiboswitchesSynthetic Rna Regulons
RNA molecules perform diverse regulatory functions, and while synthetic RNA-based control devices have been demonstrated mainly in bacteria and yeast, their extension to mammalian gene‑expression control and functional response regulation has been limited. The study aims to develop a synthetic RNA‑based regulatory system that links drug‑responsive ribozyme devices to growth cytokine targets to control T‑cell proliferation. The system employs ribozyme‑based regulatory devices that respond to drug inputs to modulate cytokine expression in mouse and primary human T cells. The controllers effectively modulate T‑cell growth rates in vivo, adapt to diverse ligand inputs and targets, offer tunable regulatory stringency and rapid response, thereby providing tight gene‑expression control that can enhance cellular therapies.
RNA molecules perform diverse regulatory functions in natural biological systems, and numerous synthetic RNA-based control devices that integrate sensing and gene-regulatory functions have been demonstrated, predominantly in bacteria and yeast. Despite potential advantages of RNA-based genetic control strategies in clinical applications, there has been limited success in extending engineered RNA devices to mammalian gene-expression control and no example of their application to functional response regulation in mammalian systems. Here we describe a synthetic RNA-based regulatory system and its application in advancing cellular therapies by linking rationally designed, drug-responsive, ribozyme-based regulatory devices to growth cytokine targets to control mouse and primary human T-cell proliferation. We further demonstrate the ability of our synthetic controllers to effectively modulate T-cell growth rate in response to drug input in vivo. Our RNA-based regulatory system exhibits unique properties critical for translation to therapeutic applications, including adaptability to diverse ligand inputs and regulatory targets, tunable regulatory stringency, and rapid response to input availability. By providing tight gene-expression control with customizable ligand inputs, RNA-based regulatory systems can greatly improve cellular therapies and advance broad applications in health and medicine.
21
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
Richard A. Morgan, Mark E. Dudley, John R. Wunderlich et al. · Science · 2006 · 2.6K citations · Full text
Medicine, Immunology, Oncology +14
Elizabeth Walter, Philip D. Greenberg, M. Jean Gilbert et al. · New England Journal of Medicine · 1995 · 1.8K citations
Cassian Yee, John A. Thompson, D. Byrd et al. · Proceedings of the National Academy of Sciences · 2002 · 1.2K citations
Medicine, Immunology, Oncology +17
High-Resolution Molecular Discrimination by RNA
Robert Jenison, Stanley C. Gill, Arthur Pardi et al. · Science · 1994 · 1.2K citations
Pharmacy, Biochemistry, Pharmacology +17